Skip to content
Facebook page opens in new windowInstagram page opens in new windowYouTube page opens in new window
Search:
DONATE
ALD Connect
ALD ConnectALD Connect
  • About Us
    • Mission
    • Board of Directors
    • The Myelin Project
    • Our Partners
  • What is ALD?
    • ALD Centers and Experts
    • Newborn Screening/Asymptomatic
    • Adrenal Insufficiency
    • Cerebral ALD
    • Adrenomyeloneuropathy (AMN)
    • Symptomatic Women
  • Clinical Trials & Research
    • Clinical Trials
    • Emerging Investigators
    • The Grey Zone
    • Laboratories
    • Publications
  • Resources
    • Annual Meetings and Patient Learning Academies
    • EL-PFDD
    • Financial Assistance
    • Frequently Asked Questions
    • Peer Mentor Program
    • Webinars
  • Get Involved
    • Advocate
    • ALD Landscape Project
    • Community Calendar
    • Community Calls
    • Community Directory
  • News
  • Contact Us
  • About Us
    • Mission
    • Board of Directors
    • The Myelin Project
    • Our Partners
  • What is ALD?
    • ALD Centers and Experts
    • Newborn Screening/Asymptomatic
    • Adrenal Insufficiency
    • Cerebral ALD
    • Adrenomyeloneuropathy (AMN)
    • Symptomatic Women
  • Clinical Trials & Research
    • Clinical Trials
    • Emerging Investigators
    • The Grey Zone
    • Laboratories
    • Publications
  • Resources
    • Annual Meetings and Patient Learning Academies
    • EL-PFDD
    • Financial Assistance
    • Frequently Asked Questions
    • Peer Mentor Program
    • Webinars
  • Get Involved
    • Advocate
    • ALD Landscape Project
    • Community Calendar
    • Community Calls
    • Community Directory
  • News
  • Contact Us

Communication and testing experiences of adolescent girls and adult women in families with X-linked adrenoleukodystrophy

UncategorizedBy KellySeptember 29, 2022

Research Study: Communication and testing experiences of adolescent girls and adult women in families with X-linked adrenoleukodystrophy Purpose of Research: Genetic counselors are often involved in facilitating genetic testing for…

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

UncategorizedBy KellySeptember 17, 2022

  bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) SKYSONA is the first FDA approved therapy shown to slow the progression of…

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)

UncategorizedBy KellySeptember 14, 2022

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD) 2022-09-14 Mataró, Barcelona, Spain, September 14, 2022 – Minoryx Therapeutics, a late-stage biotech company…

ALD Family Weekend

UncategorizedBy KellyJune 23, 2022

ALD Family Weekend

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

UncategorizedBy KellyJune 9, 2022

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a…

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions

UncategorizedBy KellyMay 18, 2022

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions New funding will support ongoing clinical development of lead candidate, SBT101 for adrenomyeloneuropathy (AMN)…

Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy

UncategorizedBy KellyMay 17, 2022

Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy LYON, France–(BUSINESS WIRE)– POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative…

Natalie Grant presents at 2022 AAN Meeting

UncategorizedBy KellyMay 5, 2022

Natalie Grant presents at 2022 AAN Meeting Natalie Grant, Clinical Research Coordinator, at Massachusetts General Hospital presented, “Neurological Disease Burden in Females with X-Linked Adrenoleukodystrophy” at the 2022 American Academy…

Dr. Jonanlis Ramirez Alcantara presents at the 2022 Pediatric Endocrine Society Meeting

UncategorizedBy KellyApril 30, 2022

Dr. Jonanlis Ramirez Alcantara presents at the 2022 Pediatric Endocrine Society Meeting Dr. Jonanlis Ramirez Alcantara, Clinical and Research Fellow at Massachusetts General Hospital, presented, “ADRENAL INSUFFICIENCY IN PEDIATRIC PATIENTS…

Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

UncategorizedBy KellyApril 14, 2022

Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments Original post by the Food and Drug Administration on Apr 13, 2022 The Food…

→12345→
© ALD Connect | Website Design & Website Development by Surf Your Name.
Go to Top